Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1982 1
1984 2
1986 2
1987 1
1988 1
1990 1
1991 1
1992 5
1994 1
1995 1
2010 1
2014 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Toric unstable resonators.
Ferguson TR, Smithers ME. Ferguson TR, et al. Appl Opt. 1984 Jul 1;23(13):2122. doi: 10.1364/ao.23.002122. Appl Opt. 1984. PMID: 18212958 No abstract available.
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
Larkin JM, Ferguson TR, Pickering LM, Edmonds K, James MG, Thomas K, Banerji U, Berns B, de Boer C, Gore ME. Larkin JM, et al. Among authors: ferguson tr. Br J Cancer. 2010 Oct 12;103(8):1149-53. doi: 10.1038/sj.bjc.6605889. Epub 2010 Sep 14. Br J Cancer. 2010. PMID: 20842130 Free PMC article. Clinical Trial.
Inherently injected unstable resonators.
Ferguson TR. Ferguson TR. Appl Opt. 1986 Feb 15;25(4):581. doi: 10.1364/ao.25.000581. Appl Opt. 1986. PMID: 18231216 No abstract available.
Unstable optical resonators with linear magnification.
Smithers ME, Ferguson TR. Smithers ME, et al. Among authors: ferguson tr. Appl Opt. 1984 Oct 15;23(20):3718. doi: 10.1364/ao.23.003718. Appl Opt. 1984. PMID: 18213218 No abstract available.
Longitudinal modes of hybrid ring lasers.
Ferguson TR, Rinaldi SM. Ferguson TR, et al. Appl Opt. 1990 Feb 20;29(6):754-62. doi: 10.1364/AO.29.000754. Appl Opt. 1990. PMID: 20556179
21 results